Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
AdvanTIG-302
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- NCT04746924 ↗
- Terminated
- BeiGene
- Focused
We haven't built an HCP commentary report on AdvanTIG-302 (ociperlimab plus tislelizumab in untreated PD-L1-selected locally advanced, unresectable or metastatic NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AdvanTIG-302 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Non-small Cell Lung Cancer; NSCLC
- Interventions
- Tislelizumab; Ociperlimab; Pembrolizumab; Placebo
- Arms
- Arm A: Ociperlimab plus Tislelizumab · Experimental
- Arm B: Pembrolizumab plus Placebo · Active comparator
- Arm C: Tislelizumab plus Placebo · Placebo comparator
- Safety Run-In Substudy · Experimental
- Enrollment
- 669
- Primary outcomes
- Overall Survival (OS) in Arms A and B
- Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)
- Safety Run-In Substudy: Serum Concentration of Ociperlimab
- Sponsor
- BeiGene
- Start
- May 24, 2021
- Primary completion
- May 30, 2025
- Results posted
- Yes
- Registry record
- NCT04746924 · updated May 12, 2026
Publications
linked from the registry- Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 >/=50. J Thorac Oncol. 2026 Jul 14:104089. doi: 10.1016/j.jtho.2026.104089. Online ahead of print. PubMed 42448175